Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® Antibiotics specialty page provides antibiotics-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Top Infectious Disease News of the Week—February 4, 2018
In case you missed them, we've compiled the top five infectious disease articles from this past week.
Paratek Submits NDAs for Oral & IV Formulations of Omadacycline
The broad-spectrum investigational antibiotic has been developed for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Antibiotic First Discovered Decades Ago May Stop Resistant Superbugs
Superbugs resistant to colistin – a last-resort antibiotic – may have a new foe in octapeptins, antibiotics discovered decades ago that recently have been found to be effective against multidrug-resistant gram-negative bacteria.
Motif Bio Receives Award for More Iclaprim Testing
The Cystic Fibrosis Foundation has awarded Motif Bio with $120,000 that will fund in vitro testing for the development of iclaprim to benefit patients with cystic fibrosis who have lung infections.
AVYCAZ Approved to Treat HABP/VABP
The FDA has approved Allergan's sNDA to expand the approved use of AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.
WHO's New Surveillance System Finds High Levels of Antibiotic Resistance Worldwide
The World Health Organization (WHO) released its first report on antibiotic resistance surveillance data.
Can Breathing Exercises Reduce the Risk of Postoperative Infections & Antibiotic Use Following Abdominal Surgery?
Historically, postoperative pulmonary complications have been the most common serious adverse event following upper abdominal surgery, with incidence rates ranging from 10% to 50%.
Big Pharma's Role in Addressing the Challenge of Antimicrobial Resistance Assessed During World Economic Forum
More than $2 billion was invested in research and development relevant to the issue of antimicrobial resistance in 2016 alone.